Makers of daily grooming and hygiene products — shampoo, toothpaste, soap, skincare and cosmetics people use every day.
Contains
News movingPersonal Care Products
United StatesBrazil
Personal Care Products▲
PTC to Be Acquired by Schneider Electric for $205 Per Share
PTC agreed to be acquired by Schneider Electric for $205 per share, valuing the software company's equity at more than $22 billion, with the transaction expected to close by the third quarter of 2027. PTC shares surged 36% premarket on the news. Brazilian stocks rallied after right-wing presidential candidate Flavio Bolsonaro edged out incumbent Luiz Inacio Lula Da Silva by around 2 percentage points in Sunday's election, sending the iShares MSCI Brazil ETF up 12% and U.S.-listed shares of Itau Unibanco and Banco Bradesco up more than 13% each. Wells Fargo gained 1% after a Morgan Stanley upgrade to overweight from equal weight, while DraftKings popped over 5% on a Bank of America upgrade to buy from neutral, with analyst Julie Hoover expecting prediction markets to generate $400 million in fees for 2027 and between $200 to $400 million in market making. Estee Lauder rose 2.8% after Barclays upgraded the stock to overweight from equal weight, citing its growth and earnings profile over the next several years.
APCO launches BIM AD brain health product, aiming to boost second-half 2026 sales
APCO has launched a new product, BIM AD, for brain health care, building on its expertise in stem cells and immune-boosting innovation derived from mangosteen extract, as it moves into the preventive wellness market. Professor Dr. Picheth Viriyachitra, Chief Executive Officer of Asian Phytocuticals Public Company Limited, or APCO, said on 5 October 2026 that the company plans to publish the research behind this innovation in an international academic journal within October. On marketing plans, the company is focusing mainly on the domestic market, targeting consumers aged 40 and over, and using the BIM Advisor model as a channel to expand its customer base alongside health education. APCO expects the launch of BIM AD to help broaden its customer base in the brain health segment and drive sales growth in the second half of this year.
APCO.BK · Demand · Positive Company expects the BIM AD launch and BIM Advisor channel to broaden its customer base and drive second-half 2026 sales growth.
APCO.BK · Technology · Positive APCO launched BIM AD, a new stem-cell/mangosteen-derived brain health product, and plans to publish its research.
KAMART approves share buyback of 30 million shares worth 218 million baht, starting October 6
KAMART, or Carmart Public Company Limited, informed the Stock Exchange of Thailand that its board of directors, at a meeting on October 2, 2026, approved a share buyback program for financial management with a maximum value of no more than 218 million baht. The number of shares to be repurchased will not exceed 30 million shares, representing no more than 2.34% of all issued and paid-up shares. The buyback will be carried out through automatic matching via the exchange's trading system from October 6, 2026 to April 5, 2027, or within six months. For the pricing criteria, the company will take the average share price over the past 30 trading days into consideration, and the buyback price must not exceed 115% of the average closing price over the five trading days preceding the transaction date. The average share price over the past 30 trading days, based on data disclosed by the company, stands at 6.86 baht per share. KAMART stated that the buyback aims to keep the market moving reasonably and to manage the company's liquidity efficiently. After the buyback, shareholders will benefit from higher return on equity, or ROE, and higher earnings per share, or EPS, while the number of shares traded on the exchange will decrease. On its financial position, the company has retained earnings of 817.19 million baht, while liabilities due within six months from the start of the buyback stand at 761 million baht. As of October 1, 2026, net cash flow from operating activities was 728 million baht. The company also expects about 943 million baht in cash flow from operations in the six months after the third quarter of 2026, and therefore assesses that it has sufficient liquidity to repay its debts and carry out the buyback program.
KAMART approves share buyback of up to 30 million shares, worth 218 million baht
Karmart Public Company Limited, or KAMART, announced that its Board of Directors, at its 5/2569 meeting held on 2 October 2569, approved a share buyback programme for financial management purposes with a maximum value of no more than 218 million baht. The company will buy back no more than 30 million shares, or no more than 2.34% of its total issued and paid-up shares. The buyback will be carried out through the Stock Exchange of Thailand's trading system using the Automatic Order Matching method. The buyback period runs from 6 October 2569 to 5 April 2570.
KAMART Surges 8.27% on News of 30 Million Share Buyback Worth 218 Million Baht
Shares of Karmart Public Company Limited, or KAMART, jumped sharply by 8.27% after the company's board approved a share buyback program for financial management purposes. As of 11:14 a.m. on October 5, 2026, the price stood at 7.20 baht, up 0.55 baht, or 8.27%, having hit an intraday high of 7.35 baht and a low of 6.95 baht, with trading value of approximately 23.36 million baht. The board resolved on October 2, 2026, to approve a buyback of no more than 30 million shares through trading on the Stock Exchange of Thailand, representing 2.34% of paid-up shares, with a maximum buyback value of 218 million baht. The program will run from October 6, 2026, to April 5, 2027. The buyback is intended for the company's financial management and has helped fuel interest in KAMART shares during this morning's trading session.
APCO launches BIM AD to enter brain health market, targeting consumers aged 40 and over
Asian Phytocuticals Public Company Limited, or APCO, has launched BIM AD, a new product for brain health care, building on its expertise in immunotherapy from mangosteen extract to expand its portfolio in the Brain Health segment and move into the preventive wellness market. Professor Dr. Pichet Wiriyachitra, Chief Executive Officer, said BIM AD was developed by combining knowledge of stem cells and immunotherapy innovation through the concept of stimulating stem cells involved in the body's tissue creation and repair processes, aiming to support brain health care and long-term internal organ recovery. The company plans to publish the research on this innovation in an international academic journal within October. For its marketing plan, the company will focus mainly on the domestic market, targeting consumers aged 40 and over, and will use the BIM Advisor model as a channel to expand its customer base alongside health care education. Professor Dr. Pichet said APCO is a leader in stem cell care and recovery using natural innovations, and he believes the launch of BIM AD will help expand its customer base in the Brain Health segment and drive sales growth in the second half of this year.
APCO.BK · Technology · Positive APCO launched BIM AD, a new brain-health product built on its stem-cell/immunotherapy innovation, expanding its portfolio into the Brain Health segment.
APCO.BK · Demand · Positive Company targets domestic consumers aged 40+ via the BIM Advisor channel, aiming to expand its customer base and drive H2 sales growth.
KAMART jumps 8% on plan to buy back up to 30 million shares starting October 6
Shares of Karmart Public Company Limited, or KAMART, climbed 8.27% after the company's board approved a share buyback program for financial management. At 10:35 a.m., the stock stood at 7.20 baht, up 0.55 baht, with a high of 7.35 baht and a low of 6.95 baht, on trading value of 21.70 million baht. The buyback sets a maximum amount to be determined by management, but no more than 30 million shares, representing no more than 2.34% of all issued and sold shares. The buyback period runs from October 6, 2026 to April 5, 2027.
APCO launches BIM AD brain health product, targeting Preventive Wellness market to boost second-half sales
Asian Phytocuticals Public Company Limited, or APCO, has launched a new product, BIM AD, for brain health care, building on its knowledge of immunotherapy from mangosteen extract to expand its portfolio in the Brain Health segment and tap the Preventive Wellness market, in line with the growing trend of consumers placing greater emphasis on preventive health care. Professor Dr. Picheth Viriyachitra, Chief Executive Officer, said BIM AD was developed by extending stem cell knowledge combined with immunotherapy innovation from mangosteen extract, through the concept of stimulating stem cells involved in the body's tissue creation and repair processes, aiming to support brain health care and long-term internal organ recovery. The company plans to publish the research on this innovation in an international academic journal within October. As for its marketing plan, the company will focus mainly on the domestic market, targeting consumers aged 40 and above, and using the BIM Advisor model as a channel to expand its customer base, alongside providing accurate knowledge and information about health care. This is expected to help broaden its customer base in the Brain Health segment and drive sales growth in the second half of this year.
APCO.BK · Technology · Positive APCO launched BIM AD, a new brain-health product built on its mangosteen-extract immunotherapy innovation, expanding its portfolio.
APCO.BK · Demand · Positive Company targets the growing Preventive Wellness market and consumers aged 40+, expecting broader customer base and second-half sales growth.
KAMART approves share buyback of up to 30 million shares, starting October 6, 2026
KAMART Public Company Limited, or KAMART, disclosed that its board of directors meeting approved a share buyback program for financial management purposes, with the maximum amount to be used for the buyback to be determined by management, but not exceeding 30 million shares, representing no more than 2.34 percent of total issued and paid-up shares. The buyback period is set from October 6, 2026 to April 5, 2027.
Betaini's first self-developed medical aesthetic injectable BTN001 approved, first interim dividend launched simultaneously
Betaini's self-developed injectable sodium hyaluronate solution BTN001 has officially received approval from the National Medical Products Administration, obtaining a Class III medical device registration certificate with registration number 20263131919. This is the group's first self-developed Class III medical device approved for market. Institutional research reports note that Betaini, leveraging its Winona sensitive-skin base and Acoman clinical channel, uses BTN001 to close the loop of pre-operative stabilization, intra-operative injection, and post-operative repair, strengthening its full-cycle medical aesthetic service capability. The new product is restricted to medical institutions, with high barriers and large pricing space, and is expected to open a second growth curve. In terms of shareholder returns, as of August 31, 2026, the company had cumulatively repurchased 3.6997 million shares, accounting for 0.8734% of total share capital, with a total transaction amount of approximately 120 million yuan. At the same time, it launched its first interim dividend, proposing a cash dividend of 1.50 yuan per 10 shares to all shareholders, with an estimated total payout of approximately 62.639 million yuan. Controlling shareholder Guo Zhenyu also pledged in April this year not to reduce his holdings within 12 months. In the first half of 2026, Betaini achieved operating revenue of 2.592 billion yuan, up 9.27% year-on-year, net profit attributable to the parent of 292 million yuan, up 18.30% year-on-year, and non-GAAP net profit attributable to the parent of 246 million yuan, a sharp increase of 34.85% year-on-year. Net cash flow from operating activities was 394 million yuan, up 13.53% year-on-year. Gross margin reached 74.62%, and the selling expense ratio fell 3.64 percentage points year-on-year to 50.53%. However, Betaini's share price has fallen about 15% cumulatively this year, hovering around 30 to 35 yuan from late June to late September. As of September 30, it closed at 32.70 yuan per share, with a latest total market value of approximately 13.8 billion yuan.
300957.CS · Capital · Positive Company launched its first interim dividend of 1.50 yuan per 10 shares and had cumulatively repurchased 3.6997 million shares for ~120 million yuan.
300957.CS · Technology · Positive Betaini's first self-developed Class III medical device BTN001 (sodium hyaluronate injectable) received NMPA approval, opening a second growth curve.
Moody's Ratings has downgraded Edgewell Personal Care Co's corporate family rating to B1 from Ba3, citing elevated leverage, modest free cash flow and persistent profitability headwinds. The agency revised Edgewell's outlook to stable from negative, signaling the consumer products maker may be reaching an operational turning point after a period of heavy restructuring. The downgrade reflects a balance sheet burdened by debt-to-EBITDA leverage that reached 9.2x on a Moody's-adjusted basis, driven higher by restructuring expenses and costs linked to consolidating its wet shave manufacturing network. While management affirmed its full-year guidance after returning to modest organic sales growth in North America during the third quarter of 2026, credit analysts expect leverage to remain elevated in the 6x range through 2027 even as earnings recover. Edgewell's portfolio reshaping, headlined by the February 2026 sale of its lower-margin Feminine Care division, has provided a substantial liquidity cushion, though stranded costs continue to weigh on short-term profitability, and Moody's called ongoing dividend payments and share repurchases aggressive financial policy given current debt levels. The stable outlook hinges on profitability expanding as transformation initiatives take hold, with an upgrade requiring debt-to-EBITDA leverage below 4.5x alongside sustained organic revenue growth, while a failure to bring leverage below 5.5x could trigger further negative rating actions.
EPC · Capital · Negative Moody's downgraded Edgewell's corporate family rating to B1 from Ba3 on elevated leverage (9.2x), modest free cash flow and profitability headwinds.
KAMART Approves New 30 Million Share Buyback, Starting October 6, 2026
The board of Karmart, or KAMART, has approved a share buyback program for financial management of 30 million shares, representing 2.34% of paid-up shares. The shares will be purchased on the stock exchange between October 6, 2026 and April 5, 2027. Earlier, in mid-2025, the KAMART board approved a buyback of no more than 30 million shares within a period of no more than six months. Most recently, KAMART shares closed at 6.65 baht, compared with a book value of 2.74 baht per share, representing a P/BV of 2.43 times and a P/E of 12.96 times.
KAMART approves share buyback of 30 million shares, running from 6 Oct 2026 to 5 Apr 2027
Karmart Public Company Limited, or KAMART, has informed the Stock Exchange of Thailand that its board of directors, at its 5/2026 meeting held on 2 October 2026, approved a share buyback programme for financial management purposes. The company will buy back no more than 30,000,000 shares, or approximately 2.34% of its total issued shares, through the Stock Exchange of Thailand. The programme will run from 6 October 2026 to 5 April 2027. On pricing, the company stated that the buyback price will not exceed 115% of the average closing price over the five trading days preceding the transaction date. The average closing price over the 30 trading days before the disclosure was 6.86 baht per share. KAMART said the buyback is intended to keep the market moving in a reasonable direction and to improve liquidity management efficiency. Following the buyback, the company expects its return on equity and earnings per share to increase.
Oddity Tech Analyst Price Targets Rise to US$16 to US$18 After Q2 Results
Several Wall Street firms raised their price targets on Oddity Tech into the US$16 to US$18 range following the company's recent Q2 results and updated guidance. Morgan Stanley, Jefferies and Truist lifted targets into the mid to high teens, while Truist, Jefferies and JPMorgan pointed to the scale of Oddity Tech's data driven platform and the contribution from Spoiled Child and MethodIQ as key supports for the equity story. Goldman Sachs and Jefferies noted that Q2 earnings and sales came in ahead of expectations, with management guiding to improved sales trends into Q3. Goldman Sachs and BofA kept cautious views in place with Sell and Underperform ratings, and Morgan Stanley, Truist, Jefferies and JPMorgan all flagged uncertainty around the timing and strength of any IL Makiage recovery. The estimated fair value per share moved from about US$11.07 to US$15.31, with the revenue growth assumption rising from about 2.78% to roughly 7.74% and the net profit margin assumption moving from around 2.22% to about 5.39%.
ODD · Capital · Positive Wall Street firms raised Oddity Tech price targets to US$16-US$18 after Q2 earnings and sales beat expectations and guidance improved.
dsm-firmenich completes €540 million share repurchase program
dsm-firmenich has completed its €540 million share repurchase program, the company announced on October 1, 2026. The program, launched on March 12, 2026, was split between €40 million to cover commitments under the Group's share-based compensation plans and €500 million to reduce issued capital. In the final window from September 28 through September 30, 2026, the company repurchased 193,100 shares at an average price of €98.62 per share for a total of €19.0 million. Across the full program, dsm-firmenich repurchased 7,169,147 shares at an average price of €75.32, of which 680,701 shares were for share-based compensation plans and 6,488,446 shares were for capital reduction. The company intends to cancel the 6,488,446 capital-reduction shares by the end of the first quarter of 2027, cutting issued shares by approximately 2.6% from 253,626,947 to 247,138,501.
DSFIR.AS · Capital · Positive dsm-firmenich completed its €540 million share repurchase program and will cancel 6,488,446 shares, cutting issued capital by ~2.6%
Kimberly-Clark Launches Exchange Offers for Kenvue Notes
Kimberly-Clark has launched exchange offers and consent solicitations for Kenvue's outstanding notes tied to its pending acquisition of the company. The proposal gives Kenvue bondholders the option to swap existing securities into new Kimberly-Clark issued notes on specified terms, and the consent solicitations seek bondholder approval to amend certain covenants in Kenvue's current debt documents as part of the transaction process. The exchange offers include new Kimberly-Clark notes plus cash and early participation premiums, effectively asking bondholders to accept Kimberly-Clark as the primary borrower on refreshed terms. Kimberly-Clark, a US household products manufacturer with a market value of about $32.9b, is seeking to simplify the debt structure around the pending Kenvue acquisition and bring those obligations directly onto its own balance sheet. The clearest early sign of success will be the level of noteholder participation and whether Kimberly-Clark secures the majority consents needed to strip restrictive covenants from the Kenvue indenture.
KMB · Capital · Neutral Kimberly-Clark launches exchange offers and consent solicitations to move Kenvue's notes onto its own balance sheet as part of the pending acquisition.
KVUE · Capital · Neutral Kenvue bondholders are offered swaps into new Kimberly-Clark notes and asked to approve covenant amendments tied to Kimberly-Clark's pending acquisition of Kenvue.
Kasikorn Securities Expects NEO's Third-Quarter Profit to Surge 261%, Raises Target Price to 24.78 Baht
Kasikorn Securities estimates that NEO will post a third-quarter profit of 212 million baht, up 261% year on year and 2% quarter on quarter, under assumptions of 19.5% sales growth, a 38% gross margin, and a selling and administrative expense ratio of 29.2% of revenue. This puts the first nine months of the year at 516 million baht, up 31% year on year, or 73% of the full-year profit forecast of 705 million baht. The company is maintaining its targets for the year: double-digit sales growth, a gross margin of 37% to 39%, and an SG&A-to-revenue ratio of no more than 27%. For next year, it targets mid-to-high single-digit sales growth. The research team is keeping its hold recommendation on NEO but raising its end-of-next-year target price to 24.78 baht from 24.14 baht, after shifting the valuation base year to the end of next year, compared with the current market price of 23.7 baht.
NEO.BK · Capital · Positive Kasikorn Securities raised its target price to 24.78 baht and forecasts Q3 profit up 261% year on year, an analyst valuation/earnings call.
L'Oréal Opens Talks for Minority Stake in Giorgio Armani
L'Oréal has entered talks to acquire a minority stake in Giorgio Armani as part of a wider reshuffle at the Italian fashion house. The potential deal would deepen a long-running licensing partnership between the two groups in fragrances, cosmetics and skincare. Armani's overhaul also includes leadership changes and a refreshed brand strategy alongside the exploration of new external investors. L'Oréal, a €202.7b personal products group, already manufactures and sells cosmetics and skincare across Europe, the Americas, Asia and multiple emerging regions, so any closer link with Armani would plug directly into a wide global distribution and branding platform. The talks reinforce the part of the L'Oréal story that relies on targeted dealmaking to deepen luxury credentials and defend pricing power against groups like LVMH and Estée Lauder.
OR.PA · Capital · Positive L'Oréal is in talks to acquire a minority stake in Giorgio Armani, deepening its luxury dealmaking.
Giorgio Armani Group · Capital · Neutral Armani explores selling a minority stake to L'Oréal amid leadership and brand-strategy overhaul; outcome unclear.
Proya invests 3.13 million yuan for a 19% stake in BISHENGZHIYAN, and plans to commit 100 million yuan to a 3.1 billion yuan industry fund
Proya's wholly owned subsidiary Proya Hainan Investment Co., Ltd. has invested 3.132114 million yuan to become a new shareholder of Shanghai Kede Biotechnology Co., Ltd., the parent company of the functional skincare brand BISHENGZHIYAN, with a 19% stake. Founder Shi Nuo's shareholding has correspondingly dropped to 47.06%, but he remains the largest shareholder. Proya told 21st Century Business Herald that this transaction is a minority equity investment, does not involve control or consolidation, and BISHENGZHIYAN will continue to operate independently with its founding team leading the brand's development. Kede Biotechnology was established in December 2016 and owns the functional skincare brand BISHENGZHIYAN and the body care brand Eios. According to beauty industry media Qingyan, BISHENGZHIYAN's sales on mainstream e-commerce platforms reached 745 million yuan in 2025, and sales in the first eight months of this year were 669 million yuan, with the full year expected to approach the 1 billion yuan level. On the industrial investment side, Proya Hainan Investment Co., Ltd. plans to invest 100 million yuan to subscribe to limited partnership interests in Ningbo Zhixing Yueheng Venture Capital Partnership, a fund managed by Shanghai Zhenxin Valley Investment Management Co., Ltd. The fund's target total committed capital is 3.1 billion yuan, with an initial total committed capital of 920 million yuan. Proya has previously spent a cumulative 779 million yuan to acquire a 51% controlling stake in Flower Knows. This investment in BISHENGZHIYAN is intended to strengthen its position in the functional skincare sector, which is facing growth pressure.
603605.CG · Capital · Positive Proya invests 3.13M yuan for a 19% minority stake in BISHENGZHIYAN's parent and plans 100M yuan into a 3.1B yuan industry fund, expanding its beauty portfolio.
上海科黛生物科技有限公司 · Capital · Positive Shanghai Kede Biotechnology (BISHENGZHIYAN's parent) receives a 3.13M yuan investment from Proya for a 19% stake, valuing the brand at roughly 16.5M yuan.
珀莱雅（海南）投资有限公司 · Capital · Positive Proya Hainan Investment makes the 3.13M yuan stake purchase and plans a 100M yuan fund subscription, serving as the investment vehicle.
上海正心谷投资管理有限公司 · Capital · Neutral Shanghai Zhenxin Valley Investment Management is named only as the manager of the fund Proya plans to invest in; no direct impact stated.
BioHarvest Sciences Board Authorizes Share Buyback of Up to 1,133,392 Shares
BioHarvest Sciences said its board has authorized a share repurchase program under a normal course issuer bid, in line with Canadian market practices. Under the program, the company may repurchase up to 5% of its outstanding common shares, or a maximum of 1,133,392 shares. The normal course issuer bid is expected to begin no earlier than five days after the announcement and will remain in effect for up to 12 months, unless the maximum number of shares is repurchased or the company terminates the program earlier.
dsm-firmenich repurchases 313,835 shares for €30.3 million in latest buyback week
dsm-firmenich repurchased 313,835 of its own shares during the week of September 21 to September 25, 2026, at an average price of €96.45 per share for a total of €30.3 million. The purchases are part of a €540 million repurchase program the company began on March 12, 2026, which splits into €40 million to cover commitments under the Group's share-based compensation plans and €500 million to reduce its issued capital. The €40 million share-plan tranche was finalized on March 23, 2026, while the €500 million capital-reduction tranche is intended to be completed by the end of Q3 2026. To date, 6,976,047 shares have been repurchased under the program at an average price of €74.68, for a total consideration of €520.9 million. The program follows dsm-firmenich's February 9, 2026 announcement of its intention to buy back ordinary shares with an aggregate market value of €500 million and reduce its issued capital.
DSFIR.AS · Capital · Positive dsm-firmenich repurchased 313,835 own shares for €30.3 million under its €540 million buyback program, reducing issued capital.
L'Oréal has priced a €2b multi-tranche bond offering that includes both floating and fixed rate notes, with proceeds earmarked for general corporate purposes and admission to trading on Euronext Paris. The funding deal lands as the beauty giant's shares edge up 0.8% on a one-day basis and show a 5.6% share price return year to date, alongside a 1 year total shareholder return of 7.5% and a 5 year total shareholder return of 15.5%. The company's most followed valuation narrative puts fair value at €417.08 against a last close of €385.00, implying the bond-funded reshaping of the balance sheet is happening while the shares trade below that internal estimate. L'Oréal has pursued major capital allocation to strategic acquisitions such as Medik8 and Color Wow, plus digital and AI-driven innovation, while operational efficiencies from global IT transformation and BETiq optimization support SG&A and A&P cost discipline. Rising competition in key beauty categories and the risk of softer demand in China could still challenge L'Oréal's premium P/E narrative if sentiment turns.
Dao Brokerage Expects NEO's Q3 2026 Profit to Surge 321% to 247 Million Baht, Raises Target to 34 Baht
Dao Securities (Thailand) Public Company Limited has issued an analysis expecting Neo Corporate Public Company Limited, or NEO, to post net profit of approximately 247 million baht in the third quarter of 2026, up 321% from the same period last year and up 19% from the previous quarter, marking its highest level in six quarters. The gain is driven by revenue expected to set a new record, with the key factor being sales boosted by the "Thai Help Thai Plus" program, as well as product price increases starting in July 2026. For the fourth quarter of 2026, Dao Securities sees continued growth compared with the same period last year, benefiting from the easing of the flood situation. Meanwhile, the research team has raised its net profit forecast for NEO in 2026 by 12% to 720 million baht, up 28% from last year, and maintained its "Buy" recommendation while raising the target price to 34.00 baht from 31.00 baht.
Yiyi Shares' actual controllers plan to transfer 7% stake via agreement for 220 million yuan
Yiyi Shares announced on September 29 that its controlling shareholder and actual controller Gao Fuzhong, actual controller Gao Jian, shareholder holding more than 5% Lu Junmei and her concert party Lu Junjiang, director and deputy general manager Gao Bin, director Yang Bingfa, and employee representative director Zhang Jian signed a Share Transfer Agreement on the same day with Suqian Zhurong Investment Partnership. They plan to transfer a total of 12.95 million shares, representing 7% of the company's total share capital, to Suqian Zhurong at a price of 17 yuan per share, with a total transfer price of 220 million yuan. The announcement stated that this agreement transfer will not lead to changes in the company's controlling shareholder or actual controllers, nor will it result in a change of control of the listed company.
001206.CS · Capital · Neutral Controlling shareholders and executives transfer 7% stake to Suqian Zhurong for 220 million yuan, but control remains unchanged.
Several shareholders of Yiyi Co. plan to transfer 7% of shares by agreement at 17 yuan per share
Yiyi Co. announced that its controlling shareholder and actual controller Gao Fuzhong, Gao Jian, shareholder holding more than 5% Lu Junmei and her concert party Lu Junjiang, as well as directors Gao Bin, Yang Bingfa and Zhang Jian, have signed a Share Transfer Agreement with Suqian Zhurong Investment Partnership. The above shareholders plan to transfer a total of 12.95 million shares by agreement at a price of 17 yuan per share, accounting for 7% of the company's total share capital, with a total transfer price of 220 million yuan. After the completion of this transfer, Suqian Zhurong will become a shareholder holding more than 5% of Yiyi Co.
001206.CS · Capital · Neutral Controlling and other shareholders agreed to transfer 7% of Yiyi Co. shares at 17 yuan/share to Suqian Zhurong, a major equity/ownership change.
宿迁祝荣投资合伙企业 · Capital · Neutral Suqian Zhurong Investment Partnership is the buyer acquiring 12.95 million shares (7%) of Yiyi Co. for 220 million yuan.
Natural Alternatives Posts Q4 GAAP Loss of $2.23 Per Share on $34.5M Revenue
Natural Alternatives International reported a fourth-quarter GAAP loss of $2.23 per share on revenue of $34.5 million, up 1.9% year over year. For the fiscal year ended June 30, 2026, net sales rose $12.7 million, or 10%, to $142.5 million from $129.9 million a year earlier. The company's full-year net loss widened to $20.7 million, or $3.43 per diluted share, compared with a net loss of $13.6 million, or $2.28 per diluted share, in fiscal 2025. As of June 30, 2026, Natural Alternatives held cash of $7.5 million and working capital of $27.7 million, down from $12.3 million and $30.5 million respectively a year earlier. The shares fell 2.86%.
NAII · Capital · Negative Q4 GAAP loss of $2.23/share and widened full-year net loss of $20.7M, with cash and working capital both declining year over year.
DAOL assesses floods in 25 provinces, short-term impact on SET, lists stocks set to gain and lose
DAOL Securities (Thailand), or DAOL, assessed the flood situation in Thailand, which has now spread to 25 provinces covering 128 districts, affecting the SET Index in the short term from negative sentiment toward economic activity. However, the impact on the operating results of listed companies is expected to be limited. Bangkok and its vicinity faced continuous heavy rain during 25-27 September 2026, causing flooding in many areas, and the government declared Bangkok, Nonthaburi, Pathum Thani and Samut Prakan as special public holidays on 28-29 September to ease the impact and reduce travel by the public. The research department stated that the groups expected to benefit after the water recedes include the Home Improvement group such as HMPRO, GLOBAL and DOHOME from demand to repair homes and replace damaged goods, with a boost expected in 4Q26E. NEO, which derives 100% of its total revenue from consumer products, will benefit as consumers must buy new household items. TFMAMA benefits from consumers stockpiling goods, and TASCO benefits from road repairs after the water recedes. The groups expected to be negatively affected include the Ground Transport group such as BEM and BTS from a possible short-term decline in passenger volumes, although the waiver of expressway tolls until 29 September at 24.00 will have a limited impact because the Expressway Authority of Thailand will compensate the companies. The tourism group ERW, CENTEL, AAV and AOT is seen as slightly negative from travel concerns. The Energy group such as OR and PTG is expected to see a temporary drop in downstream oil sales volumes, with total daily retail oil sales volumes of OR and PTG at approximately 29.4 million and 15.8 million liters in 2Q26, and the number of service stations in the central, eastern and western regions of the two companies accounting for approximately 45% and 37% of their total service stations. The insurance group TIPH, TVH, MTI, BKI and AYUD must pay compensation for the floods, and the Commerce group such as CPALL, CPAXT and BJC faces rain and flooding pressuring traffic, forcing some branches to temporarily close, although stockpiling of essential goods will help offset some of the impact.
DOHOME.BK · Demand · Positive DOHOME named among home improvement stocks expected to benefit from post-flood home repair and replacement demand in 4Q26E.
ERW.BK · Demand · Negative ERW listed in tourism group seen slightly negative from travel concerns during the floods.
GLOBAL.BK · Demand · Positive GLOBAL named among home improvement stocks expected to gain from post-flood repair and replacement demand.
HMPRO.BK · Demand · Positive HMPRO named among home improvement stocks expected to benefit from post-flood home repair and replacement demand.
NEO.BK · Demand · Positive NEO derives 100% of revenue from consumer products and is expected to benefit as consumers buy new household items after the floods.
AAV.BK · Demand · Negative AAV is in the tourism group seen as slightly negative from travel concerns due to flooding.
Shouxiangu and Partners Jointly Establish Cell and Gene Venture Capital Partnership
Shouxiangu and partners have jointly funded the establishment of Hangzhou Huarui Cell and Gene Venture Capital Partnership, a limited partnership, which was recently incorporated. According to Qichacha APP, the partnership's business scope includes venture capital investment, limited to investing in unlisted companies, as well as equity investment. Qichacha equity penetration shows that the enterprise is jointly funded by Shouxiangu and others.
603896.CG · Capital · Positive Shouxiangu jointly funded and established Hangzhou Huarui Cell and Gene Venture Capital Partnership, a venture capital investment vehicle.
L'Oréal announced it has successfully priced a bond offering for an aggregate nominal amount of 2 billion euros, split into three tranches. The tranches comprise an 850 million euro 2-year floating rate bond paying a coupon of Euribor 3M plus 27 bps per annum, a 500 million euro 3-year fixed rate bond paying a coupon of 3.75 percent per annum, and a 650 million euro 7-year fixed rate bond paying a coupon of 4.00 percent per annum. The net proceeds will be used for general corporate purposes. The bond, expected to be rated AA (Stable) by S&P and Aa1 (Stable) by Moody's, will be admitted to trading on Euronext Paris from the settlement date scheduled for 30 September 2026. BNP Paribas, HSBC, and Société Générale are acting as Global Coordinators, while Crédit Agricole CIB, Deutsche Bank, ING, Santander, and Standard Chartered Bank AG are acting as Active Joint Bookrunners.
OR.PA · Capital · Positive L'Oréal successfully priced a €2bn triple-tranche bond offering, securing long-term financing for general corporate purposes.
India's CCI clears L'Oréal takeover of Onesto Labs
The Competition Commission of India has cleared L'Oréal India's acquisition of beauty and personal-care company Onesto Labs, the legal entity behind the Innovist personal-care platform. The CCI said the proposed combination pertains to the acquisition of 100% shareholding in Onesto Labs Private Limited by L'Oréal India Private Limited, and noted that a full order on the transaction is forthcoming. Onesto Labs was rebranded as Innovist in 2022 and develops and markets skincare and haircare products under brands including Bare Anatomy, Chemist at Play, SunScoop, Vinci Botanicals and Anecdote. L'Oréal disclosed in June its intention to purchase a controlling stake in Innovist, and as part of the deal Innovist's founders will hold on to a minority share and remain involved in running and expanding the company alongside L'Oréal India, with the Innovist brands set to be folded into L'Oréal's consumer products division. No financial terms of the deal have been made public.
Herbalife Board Approves $250 Million Share Buyback Over Three Years
Herbalife's board has approved a share repurchase program of up to US$250 million over three years, giving management room to buy back stock when it sees value. The company's shares have picked up modest near-term momentum, with a 1-day share price return of 2.6% and a 7-day share price return of 2.5%, though the year-to-date share price return is still down 4.6% even after a 35.3% total shareholder return over the past year. Herbalife is trading at $12.23 against a most-followed fair value view of $17, a gap that frames the new $250 million buyback as management acting while the market price still lags that narrative. The company continues to experience flat to declining volumes in several regions, with only modest improvements in constant currency net sales, and its ongoing reliance on network recruiting and regional distributor growth increases vulnerability to macroeconomic downturns and currency headwinds in emerging markets.
dsm-firmenich Repurchases 260,000 Shares for €23.9 Million in Weekly Buyback
dsm-firmenich repurchased 260,000 of its own shares during the week of September 14 to September 18, 2026, at an average price of €91.82 per share for a total of €23.9 million. The purchases form part of a €540 million repurchase program the company began on March 12, 2026, which is split between €40 million to cover commitments under its share-based compensation plans and €500 million to reduce its issued capital. The €40 million share-plan portion was finalized on March 23, 2026, while the €500 million capital-reduction portion is intended to be completed by the end of the third quarter of 2026. To date, dsm-firmenich has repurchased 6,662,212 shares under the program at an average price of €73.65, for a total consideration of €490.7 million. The company, an innovator in nutrition, health and beauty, had announced its intention to buy back shares with an aggregate market value of €500 million on February 9, 2026.
UK CMA Opens Phase 1 Review of $65 Billion McCormick-Unilever Food Merger
The UK Competition and Markets Authority has opened a Phase 1 investigation into the proposed $65 billion merger between McCormick & Company and Unilever's food business, with a deadline of November 11, 2026, for its initial decision. The regulator will assess whether the transaction could reduce competition in UK food markets, and if it finds concerns the deal could face a deeper Phase 2 review or potential remedies. The transaction would combine McCormick's spices and sauces with Unilever brands including Knorr, Hellmann's, French's and Frank's RedHot, with Unilever and its shareholders expected to own 65% of the combined company and McCormick shareholders 35%. The deal values Unilever's food business at nearly $45 billion and McCormick at about $21 billion, and Unilever's food business generated nearly €13 billion of revenue in 2025, more than one-quarter of Unilever's €50 billion of total revenue, with 53% of food sales coming from emerging markets. Unilever would receive $15.7 billion in cash from the transaction, advancing its strategy of focusing on beauty, personal care and home products.
MKC · Regulation · Neutral UK CMA opened a Phase 1 review of the McCormick-Unilever food merger, which could lead to a deeper Phase 2 probe or remedies affecting the deal.
ULVR.LSE · Regulation · Neutral UK CMA's Phase 1 investigation into the merger of Unilever's food business with McCormick could delay or impose remedies on the $65B deal.
ST Jia'ang fined 8 million yuan for false records in financial reports; three executives penalized simultaneously
ST Jia'ang announced after market close on September 18 that the company and its responsible persons had received an Administrative Penalty Decision from the Shanghai Securities Regulatory Bureau. According to the decision, ST Jia'ang's 2023 accounting error correction announcement contained false records, understating total profit for 2021 by 23.5 million yuan; its 2024 annual report also contained false records, overstating total profit for 2024 by 23.5 million yuan. The Shanghai bureau ordered the company to rectify the issues, issued a warning, and imposed a fine of 4 million yuan. Ji Min, then chairman, was fined 1 million yuan; Ji Lin, then chairman and acting board secretary, later director, president and chief financial officer, was fined 2 million yuan; and Cao Yi, then director and chief financial officer, was fined 1 million yuan. The company and the three executives were fined a total of 8 million yuan. ST Jia'ang's main business covers the research, development, production and sale of health products, health foods and health product raw materials, as well as the operation and management of elderly medical care institutions. The company was placed under investigation by the China Securities Regulatory Commission on July 11, 2025 for suspected illegal information disclosure, received a prior notice of administrative penalty on July 31, 2026, and has been subject to other risk warnings since August 4, 2026 because of false records in financial indicators in its annual report. In the first half of this year, ST Jia'ang achieved operating revenue of 140 million yuan, down 7.15 percent year on year; net profit attributable to the parent company was negative 14 million yuan, swinging from profit to loss, and its share price has fallen by more than 40 percent since the start of the year.
600530.CG · Regulation · Negative ST Jia'ang (Shanghai Jiaoda Onlly) and three executives fined 8 million yuan by the Shanghai Securities Regulatory Bureau for false records in its 2023 correction and 2024 annual report.
ST Jiaoda Onlly inflated and deflated profits by 23.5 million yuan across years; company and three executives fined 8 million yuan in total
ST Jiaoda Onlly was fined 8 million yuan in total along with three executives for shifting 23.5 million yuan in profits across years. After market close on September 18, ST Jiaoda Onlly announced that the company and Ji Min, Ji Lin, and Cao Yi had received an administrative penalty decision from the Shanghai bureau of the China Securities Regulatory Commission. The investigation found that the company's 2023 accounting error correction announcement contained false records, understating total profit for 2021 by 23.5 million yuan, equivalent to 213.52 percent of the total profit disclosed in the corrected 2021 annual report. In its 2024 annual report, the company reversed the 23.5 million yuan impairment loss that had been additionally provided for in the earlier period, overstating total profit by 23.5 million yuan, equivalent to 60.26 percent of the total profit disclosed in the 2024 annual report. As a result, the company was ordered to correct the violations, given a warning, and fined 4 million yuan; Ji Lin was fined 2 million yuan; and Ji Min and Cao Yi were each fined 1 million yuan. The company's shares have been subject to other risk warnings since August 4, 2026, with the stock abbreviation changed from Jiaoda Onlly to ST Jiaoda Onlly. In the first half of 2026, the company reported operating revenue of 140 million yuan, down 7.15 percent year on year, and a net loss attributable to the parent company of 13.973 million yuan, swinging from profit to loss compared with the same period a year earlier.
600530.CG · Regulation · Negative CSRC fined ST Jiaoda Onlly 4 million yuan and executives for false records inflating/deflating profits across 2021-2024.
Interparfums and Marquee Brands Extend Roberto Cavalli Fragrance License to 2046
Interparfums, Inc. and Marquee Brands announced a 20-year extension of Interparfums' exclusive worldwide license agreement for Roberto Cavalli and Just Cavalli fragrances, carrying the partnership through December 31, 2046. The deal covers continued creation, development and distribution of the fragrances globally, operated by Interparfums Italia Srl, the company's wholly owned Italian subsidiary based in Florence with its seat of management in Paris. Interparfums Chairman and Chief Executive Officer Jean Madar said the extension reflects the strength of Roberto Cavalli and the partnership with Marquee Brands, noting that in three years managing the license the brand has become one of the fastest-growing in the company's portfolio, with the 2025 launch of Serpentine exceeding expectations. Marquee Brands Chief Executive Officer Heath Golden said Interparfums has proven an exceptional steward of Roberto Cavalli fragrances and that extending the partnership across decades reflects the long-term role fragrance will play in the brand's global growth strategy. Interparfums has operated in the global fragrance business since 1982 and manages European operations through its 72% owned subsidiary Interparfums SA and United States operations through wholly owned subsidiaries in the United States and Italy.
IPAR · Demand · Positive Interparfums extended its exclusive worldwide Roberto Cavalli fragrance license through 2046, securing long-term rights to a fast-growing brand in its portfolio.
Marquee Brands · Demand · Positive Marquee Brands extended the Roberto Cavalli fragrance license with Interparfums for 20 years, supporting the brand's global growth strategy.
MCA Appointed Distributor for ROJUKISS and SIS2SIS Starting 1 Oct 2026
Market Connections Asia Public Company Limited, or MCA, has notified the Stock Exchange of Thailand that Rojukiss International Public Company Limited, a manufacturer and distributor of skincare products under the ROJUKISS trademark and cosmetics under the SIS2SIS trademark, has appointed MCA as a distributor of skincare products under the ROJUKISS trademark in the cream and serum categories, and cosmetics under the SIS2SIS trademark, through Traditional Trade channels nationwide, effective from 1 October 2026 onwards.
KISS.BK · Demand · Positive Rojukiss appointed MCA as a distributor for its ROJUKISS skincare and SIS2SIS cosmetics through Traditional Trade channels nationwide, expanding product distribution.
Estee Lauder Partners With Profound for Global AI Visibility Push
Estee Lauder Companies has entered a global strategic partnership with AI marketing platform Profound to improve how its brands appear across generative AI platforms. The collaboration gives Estee Lauder a portfolio-wide view of how its brands surface on major generative AI platforms including ChatGPT and Gemini, and makes it the first prestige beauty company to deploy Profound's capabilities globally across its full portfolio and implement Generative Engine Optimization at scale. Profound's agentic tools will optimize product pages, blogs, YouTube channels and other digital content so that product information, ingredients, claims and benefits are easier for large language models to understand and surface, with AI visibility insights integrated into Estee Lauder's One Operating Ecosystem. The initiative builds on Estee Lauder's digital exposure, with online sales reaching 34% of reported sales in fiscal 2026, up three percentage points year over year. Shares of the Zacks Rank #3 (Hold) company have gained 14.1% in the past month, and the stock trades at a forward 12-month P/E ratio of 27.97 versus an industry average of 22.15.
EL · Technology · Positive Estee Lauder partners with Profound to deploy Generative Engine Optimization across its brands on AI platforms like ChatGPT and Gemini
e.l.f. Beauty Launches Cosmetics Brand in Brazil Exclusively Through Sephora
e.l.f. Beauty is expanding its international footprint with the launch of e.l.f. Cosmetics in Brazil exclusively through Sephora, becoming Sephora Brazil's first mass color cosmetics offering. Sephora's Brazilian platform reaches roughly 17% of the country's population, and the move builds on the brand's relationship with Sephora in Mexico, where it has reached the No. 1 cosmetics position. International sales penetration has doubled over the past five years to 21% of net sales, still well below the more than 70% international mix cited for legacy beauty peers, and Brazil is identified as the world's third-largest cosmetics market. International net sales rose 61% year over year in the fiscal first quarter compared with 29% growth in the United States, and an expanded presence with Boots in the U.K. is planned for this fall. Shares of ELF have tumbled 33.4% over the past year compared with the industry's decline of 2.3%, and the stock trades at a forward price-to-earnings ratio of 25.76 versus the industry's average of 22.15.
ELF · Demand · Positive e.l.f. Cosmetics launches in Brazil exclusively through Sephora, expanding its international distribution and end-customer reach.
UK watchdog opens Phase 1 probe into Unilever-McCormick $44.8bn deal
The UK's Competition and Markets Authority has launched a Phase 1 investigation into McCormick & Co.'s $44.8bn acquisition of Unilever's food assets, assessing the deal's potential impact on competition in the UK. The transaction, announced in March, would see the US-headquartered seasonings and spices business take over most of the FMCG giant's food assets, including the Knorr soups and Hellmann's mayonnaise brands, but not Lipton drinks nor Unilever's operations in India, Nepal and Portugal. The CMA said it invited comments on 21 July, with interested parties given until 5 August to respond, and has set a deadline of 11 November to complete the Phase 1 probe, when it will decide whether to follow up with a more in-depth Phase 2 assessment. Last month, Unilever and McCormick decided to seek a buyer for Unilever's Colman's mustard brand, a move Unilever said was made to proactively address potential competition concerns; Colman's joins Unilever's lifestyle nutrition business, the Buavita unit, the Lipton brand and the India, Nepal and Portugal assets that are not included in the deal. Under the terms of the transaction, Unilever and its investors are to receive a mix of McCormick's existing voting and non-voting common stock equating to 65% of the combined business, with Unilever shareholders expected to own 55.1% of the enlarged group, McCormick shareholders 35% and Unilever 9.9%, alongside $15.7bn in cash subject to certain closing adjustments. The combined company, which will include McCormick brands such as Schwartz spices, French's mustard and Cholula hot sauces, will be led by McCormick CEO Brendan Foley and CFO Marcos Gabriel, with senior management representation from Unilever's food business.
MKC · Regulation · Neutral UK CMA opens Phase 1 probe into McCormick's $44.8bn acquisition of Unilever food assets, creating regulatory uncertainty for the deal.
ULVR.LSE · Regulation · Neutral CMA Phase 1 investigation into the sale of Unilever's food assets to McCormick could delay or block the $44.8bn transaction.
United States
Brazil
